Recorded on 06/25/25

In this episode, we will discuss the current state of the biopharma industry. Coming out of the pandemic, the biopharma research and development industry saw a wave of innovation and investment. However, as we move further beyond the pandemic, biopharma has begun to experience a multitude of headwinds, including the IRA, patent expirations, changes at the FDA, NIH funding cuts, and efforts to regulate drug pricing. This influx of pressure has forced the biopharma industry to rethink how it conducts its research and development programs.

To help us discuss these topics and more, we are joined by Brian Whitlock, the founder and CEO of i3 Strategic Consulting. Brian has more than 25 years of clinical development experience across the biopharma and CRO industries. Prior to i3, Brian was the VP of Strategic Sourcing and Procurement R&D for Bristol Myers Squibb, and has also spent time at Amgen and Covance.

https://go.td.com/PodcastDisclosure